AstraZeneca (AZ) has announced that its fixed-duration Calquence (acalabrutinib)-based regimens have been approved by the ...

"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

EU approves AstraZeneca’s Calquence in combo with venetoclax, with or without obinutuzumab to treat adult patients with previously untreated CLL: Cambridge, UK Saturday, June 7, ...

AstraZeneca (LSE: AZN) has received European approval for a fixed-duration regimen of Calquence (acalabrutinib) in ...

A fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) in combination with venetoclax, with or without ...

Drugmaker AstraZeneca said on Friday that it had received approval from the European Commission for fixed-duration regimens ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) announced the European Union’s approval of its fixed-duration Calquence (acalabrutinib) regimens for the treatment of adult patients with previously ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) announced the European Union’s approval of its fixed-duration Calquence (acalabrutinib) regimens for the treatment of adult patients with previously untreated ...

(RTTNews) - AstraZeneca said a fixed-duration regimen of Calquence in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union for the treatment of adult ...

OPEN The FTSE 100 was expected to open 6.2 points lower on Friday after closing 0.11% higher in the previous session at 8,811.04.

I’m here to prove that powerful phrase; after nearly 16 years living with incurable cancer, I know there’s more to my story ...